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Abstract 
Background: Pooling strategies have been used to reduce the costs of polymerase 
chain reaction based screening for acute HIV infection in populations where the 
prevalence of acute infection is low (<1%). Only limited research has been done for 
conditions where the prevalence of screening positivity is higher (>1%).  
Methods and Results: We present data on a variety of pooling strategies that 
incorporate the use of PCR-based quantitative measures to monitor for virologic 
failure among HIV-infected patients receiving antiretroviral therapy. For a prevalence 
of virologic failure between 1% and 25%, we demonstrate relative efficiency and 
accuracy of various strategies. These results could be used to choose the best strategy 
based on the requirements of individual laboratory and clinical settings, such as 
required turnaround time of results, and availability of resources.  
Conclusions: Virologic monitoring during antiretroviral therapy is not currently 
being performed in many resource constrained settings largely because of costs. The 
presented pooling strategies may be used to make such monitoring feasible and to 
optimally limit the development and transmission of HIV drug resistance in resource 
constrained settings. They may also be used to design efficient pooling strategies for 
other settings where screening involves quantitative measures. 
1. INTRODUCTION 
In high-resourced settings, the failure of antiretroviral therapy (ART) to suppress 
HIV replication (i.e. virologic failure) while a patient is receiving ART is detected by 
the regular monitoring of HIV RNA levels in the blood (viral loads) (Hammer et al., 
2006; Haubrich et al., 2001; Hughes et al., 1997).  Viral loads are not preformed 
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regularly in resource-constrained settings, where changes in CD4 cell count are used 
as a surrogate, although CD4 –based criteria have been shown to be insensitive in 
detecting virologic failure during ART (Bisson et al., 2008; Bisson et al., 2006; 
Fiscus et al., 2006; Moore et al., 2006; Petti et al., 2006). It is, therefore, imperative 
to develop and implement less expensive methods to monitor for viral replication 
during ART in resource-constrained settings to limit the development and 
transmission of drug resistant HIV (Calmy et al., 2007; Durant et al., 1999; Miller 
and Larder, 2001; Phillips et al., 2008; Smith and Schooley, 2008).  
Various efforts demonstrated that screening for HIV RNA among people 
presenting for HIV testing or blood donation can be used efficiently to identify 
individuals who were acutely infected with HIV despite a negative HIV antibody test, 
since individuals testing during the window period between acute HIV infection and 
seroconversion will escape routine detection (Busch et al., 2005; Patterson et al., 
2007; Pilcher et al., 2005; Pilcher et al., 2002). Because testing for HIV RNA in each 
blood sample would be expensive, a commonly used strategy is to pool blood 
samples from a group of individuals and perform one HIV RNA assay on a pooled 
sample (Busch, et al., 2005; Patterson, et al., 2007; Pilcher, et al., 2005; Pilcher, et al., 
2002). If the pool tests positive, individual samples or pools of smaller size might be 
tested again to identify affected individuals. Performance and advantages of different 
pooling strategies for screening purposes have been extensively investigated. In a 
landmark paper Dorfman (1943) calculated the optimal pool size for a prevalence 
ranging from 1% to 30% for a single stage pooling algorithm.  Hammick and 
Gastwirth (1994) suggest to obtain two samples per individual an form two 
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independent sets of groupings to estimate the prevalence of HIV while preserving 
confidentiality. An advantage of this procedure is that it can be efficient for a 
prevalence of up to about 30%. Brookmeyer (1999) developed an estimator of disease 
prevalence and its variance for multistage pooling studies. Westreich et al (2008) 
investigate the performance of three different pooling strategies (two hierarchical and 
one matrix based approach) to acute HIV infection. Kim et al. (2007) derive and 
compare operating characteristics of hierarchical as well as square array-based testing 
algorithms in the presence of testing error. For additional references see 
(Brookmeyer, 1999; Hammick and Gastwirth, 1994; Kim et al., 2007; Westreich et 
al., 2008)}. Nevertheless, all of the existing work is based on settings where the 
outcome is binary (disease versus no disease).  Also, the testing for HIV RNA in 
blood samples pooled from patients receiving ART to identify instances when ART is 
failing to suppress viral replication is considerably different from nucleic acid testing 
on pooled blood samples to identify instances of acute HIV infection. Specifically, 
more efficient algorithms are needed because of the higher prevalence of instances of 
virologic failure, the inherent variability of the viral load assay, and the need to 
identify lower viral load levels. In this report, we demonstrate how screening for HIV 
RNA among pooled blood samples can be used to monitor for active HIV replication 
during ART in order to identify individuals who are experiencing virologic failure. 
These results could have profound impact on the ability to virologically monitor HIV-
infected patients receiving ART in resource constrained settings and ultimately limit 
the development and transmission of drug resistant HIV strains. 
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2. METHODS  
Simulations were used to generate sample values of viral loads that represent a 
population of patients on ART. The distribution of viral load values of the simulated 
population was based on a natural history cohort of HIV infected individuals. Briefly, 
for viral load values below 500 copies/mL, 85%, 5% and 10% of values were 
generated to be uniformly distributed below 50 copies/mL, between 50 and 100 
copies/mL and between 100 and 500 copies/mL, respectively. For values above 500 
copies/mL, simulated viral load values were based on two gamma distributions with 
modes at about 1000 and 6000 copies/mL (on log10 scale the gamma location 
parameter was 2.7, scale parameter was 0.5 and shape parameter was 1.6 for the first 
and 3.18 for the second gamma distribution). The proportion of values generated for 
the first and second gamma distribution were 93% and 7% respectively. Both 
individual and pooled values were generated to include measurement error from viral 
load assay variability based on normally distributed measurement error with mean 
zero. Assay standard deviation was assumed to be zero, 0.12 and 0.20 on the log10 
scale. The value of zero represented a best case scenario, the value of 0.12 was based 
on published data (Brambilla et al., 1999) and 0.20 represented a more conservative 
alternative (Jagodzinski et al., 2000). Threshold values to define virologic failure 
during ART of 500, 1000 or 1500 copies/mL were used based on clinically 
meaningful thresholds at which drug resistance testing could be performed and 
decisions to amend therapy might be expected (Harrigan et al., 2005; Haupts et al., 
2003; Hirsch et al., 2003).  
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Three algorithms were evaluated (Figures 1 and 2). The first was based on 
Dorfman’s (Dorfman, 1943) two-stage “minipool” approach where a fixed number of 
samples would be combined into one pool. If the pooled samples yielded an assay 
value above the lower limit of interest for the pool (e.g. ≥50 copies/mL), then all 
individual samples would be tested in the second stage. Samples of pools with assay 
values below the lower limit of interest would be considered virologically suppressed 
and no further tests would be performed. For the second algorithm, minipools would 
be formed in the same manner as for Dorfman’s approach; however, if the pooled 
samples yielded a viral load value above the lower limit of interest, then individual 
samples would be tested consecutively (in random order) and subtracted from the 
pooled sample estimate until the lower limit of interest for the pool was achieved. We 
call this approach “minipool + algorithm”. The third approach applied a similar 
algorithm to a k by k matrix. For this approach, samples would be organized in a 
matrix structure and pools formed over k rows and k columns. Samples of pools 
would be considered virologically suppressed if either the row or column pools 
yielded values below the threshold of interest. After obtaining (k + k) values for pools 
across rows and columns, individual samples would be consecutively tested based on 
the order of highest column and row value, i.e. the individual sample that resides in 
the matrix at the intersection of the row and column pools with the highest viral load 
values would be tested individually. Viral load values from the individual test would 
then be subtracted from the appropriate column and row pool totals, and individual 
testing would proceed one sample at a time until no further row and column pools 
had values above the lower level of interest. If a single row (or column) showed a 
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value above the lower limit of interest, but none of the columns (or rows) did, all 
samples from such a row (or column) would be considered virologically suppressed.  
Based on various prevalences of and thresholds for defining virologic failure, we 
compared relative efficiency and negative predictive value for four approaches 
(individual samples, minipool, minipool + algorithm and matrix approach) and 
various pool sizes within each of the pooling approaches (minipool, minipool + 
algorithm and matrix approaches). Relative efficiency was defined as one minus the 
average number of assays performed divided by the number of samples. We use a 
different definition of efficiency than others (Westreich, et al., 2008) because of the 
natural interpretation that the best algorithm will have the highest values of efficiency 
relative to individual testing. With this definition, an algorithm with efficiency zero 
has no advantage over individual testing and an algorithm with efficiency of 0.25 
uses 25% fewer samples than would be used with individual testing.  
Negative predictive values were compared for the various approaches to identify 
individual samples that had viral load values below the same range of thresholds 
(500, 1000 and 1500 HIV RNA copies/mL) similar to the comparisons of relative 
efficiency. For our purposes, the negative predictive value was the proportion of 
individuals who were virologically suppressed below the threshold of interest (true 
and test negative) among those who were considered suppressed by each proposed 
method (test negative).  
Additionally, we evaluated the various approaches in the context of the following 
clinically relevant factors: 1) level of viral load for defining virologic failure, 2) 
standard deviation of the viral load assay and 3) prevalence of virologic failure in the 
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sampled population. Screening approaches for higher prevalence of virologic failure 
and assays with larger standard deviation were expected to be less efficient than for 
lower prevalence of virologic failure or assays with smaller standard deviation. 
Pool sizes of 3, 4, 5, 6, 7, 8, 10 and 20 were considered. Since the lowest possible 
level of viral load detection depends on the dilution factor of the pool, the level of 
detection was considered in relation to the size of the pool. For example, with a lower 
detection limit for a viral load assay of 50 copies/mL and a pool size of 10, the on 
average lowest level of virologic failure that we can expect to detect for any 
individual sample based on the pooled analysis was 500 copies/mL. When pools of 
20 individual samples were considered, the lowest detectable level of virologic failure 
was 1000 copies/mL. All simulations were run using the statistical software Stata 
(StataCorp, 2007) and were repeated one thousand times for all conditions. 
 
3. RESULTS 
3.1 Relative efficiency 
Of the three pooling approaches, most demonstrated relatively high efficiency 
(>0.70) when the prevalence of virologic failure was low (<3%) (Figure 3), i.e. less 
than 30% of viral load assays would be used in a pooling approach relative to 
performing viral loads for each individual sample. When the prevalence of virologic 
failure was higher (>3%), relative efficiency varied markedly, Dorfman’s (Dorfman, 
1943) minipools showed lower relative efficiency than algorithms that used the 
quantitative information available. A matrix approach with intermediate pool size (8 
or 10) appeared to be the most efficient approach when: 1) virologic failure was 
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defined as ≥1500 copies/mL, 2) the standard deviation of the assay was 0.12 and 3) 
the prevalence of virologic failure of the sampled population was between 5% and 
20%. Specifically, the relative efficiency for the matrix approach with a pool size of 
10 ranged from 0.68 to 0.33 and for a matrix approach with a pool size of 8 it ranged 
from 0.65 to 0.32 when the prevalence of virologic failure was 5% and 20%, 
respectively. Among the approaches that use the minipools + algorithm, the one with 
5 samples per pool appeared most efficient under similar conditions with relative 
efficiency from 0.63 to 0.26 for a prevalence of virologic failure of 5% and 20%, 
respectively. Thus, the relative efficiency of the 5 minipool+algorithm was close (no 
more than 0.07 difference) to the most efficient matrix approaches. The relative 
efficiency over the various approaches changed only slightly when the standard 
deviation of the assay was 0.20. For example, when the prevalence of virologic 
failure was 5% in the sampled population, the relative efficiency for the matrix 
approach with a pool size of 10 was: 1) 0.66 when the standard deviation of the viral 
load assay was 0.20, 2) 0.68 when the standard deviation was 0.12, and 3) 0.73 when 
the standard deviation was zero. For Dorfman’s minipool approach, the most efficient 
pool size was 3 (compare Dorfman (Dorfman, 1943), Table 1) with relative efficiency 
ranging from 0.52 to 0.13 when the prevalence of virologic failure was 5% and 20%, 
respectively. 
Overall, pool sizes of 3 and 4 had the highest relative efficiency among the 
minipool and minipool + algorithm approaches and a pool size of 10 had the highest 
relative efficiency among the matrix approaches when the prevalence of virologic 
failure was between 5% and 20% (Figure 4). Results were not substantially different 
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when virologic failure was defined as ≥500, ≥1000 copies/mL or ≥1500 copies/mL. 
For example, when using the matrix approach with a pool size of 10, assay SD of 
0.12 and a prevalence of virologic failure of 20%, the relative efficiency was 0.68 
when virologic failure was defined at ≥1500 copies/mL, 0.66 at ≥1000 copies/mL and 
0.65 at 500 copies/mL.  
 
3.2 Negative predictive values 
The results for negative predictive values were uniformly good. For a prevalence 
of virologic failure up to 10%, negative predictive values were at least 99% and 97% 
for the matrix approach with assay standard deviations of 0.12 and 0.20 copies/mL 
respectively. Similarly, the corresponding negative predictive values were 99% and 
98% for all minipool + algorithm approaches.  For a prevalence of virologic failure 
up to 20%, negative predictive values were always at least 92% for all matrix 
approaches and always above 96% for the minipool + algorithm approach when the 
standard deviation of the assay was 0.12. These results changed only minimally for 
an assay standard deviation of 0.20. Negative predictive values were always higher 
than 99% for Dorfman’s minipool approach (without algorithm). These results 
remained virtually unchanged for different definitions of virologic failure (500, 1000 
and 1500 HIV RNA copies/mL).  
 
3.3 Other factors 
In addition to relative efficiency and negative predictive value, there are other 
factors which can influence the clinical utility of these approaches. One is the local 
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need of turnaround time of the results, which will depend on availability of the 
assays, personnel performing the assays and size of the clinical population receiving 
ART. The proposed pooling strategies will vary in the time from sample collection to 
the time individual viral load results are available to the clinician for management of 
their patients. For example, if a laboratory has the capability of performing 20 viral 
loads a day, then 20 individuals could be screened daily using individual viral load 
testing and it would take 5 days to screen 100 individuals. If minipools of size 5 are 
used, then 100 individuals could be screened in the first day, but some pools would 
require additional testing and, therefore, additional days would be required before 
results are available. The number of additional days would depend on the prevalence 
of virologic failure in the sampled population and the specific pooling approach. 
When 100 patients are screened using minipools of size 5 + algorithm and virologic 
failure is defined as ≥1500 HIV RNA copies/mL and the prevalence of virologic 
failure is 10%, there would be an average of 2 days until the viral loads of all samples 
have been resolved. Similarly, the initial screening of the same 100 patients using the 
matrix approach with a pool size of 10 would require one day, but the complete 
resolution of all samples would require on average 28 days (1 day for testing all row 
and column pools and an average of about 27 days for 27 individual assays that must 
be tested consecutively); however, on average 65% of the individual samples would 
have been resolved on the first day.  
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4. DISCUSSION 
Because commercial viral load assays cost between US $50.00–$150.00 per test 
[Clinton Foundation. Diagnostics pricing. Available at: 
<http://www.clintonfoundation.org/cf-pgm-hs-ai-work3.htm>; Accessed May 23, 
2008. (Fiscus, et al., 2006)] the costs of virologic monitoring during ART may 
exceed those of ART itself, but the development and transmission of drug resistant 
HIV may ultimately compromise the effectiveness of ART in many populations 
(Harrigan, et al., 2005; Haupts, et al., 2003; Little et al., 2002; Miller and Larder, 
2001; Vijayaraghavan et al., 2007).  In resource-constrained settings less expensive 
methods to monitor viral replication during ART are necessary to make such 
monitoring feasible and ART sustainable. In this report, we demonstrate how nucleic 
acid testing on pooled blood samples can be used to reduce the overall number of 
viral load tests needed to screen patients receiving ART compared to individual 
testing.  
Since the prevalence of virologic failure in the sampled population will impact the 
relative efficiency and accuracy of the presented pooling and testing methods, other 
strategies that can identify individuals with virologic failure before nucleic acid 
testing could greatly increase the usefulness of the proposed methods. Such strategies 
include the measurement of adherence to ART (Bisson, et al., 2008; Gifford et al., 
2000; Haubrich et al., 1999; Paterson et al., 2000) or longitudinal trajectory of CD4 
counts (Bisson, et al., 2008); however, these methods are by no means perfect 
predictors of virologic failure (Bisson, et al., 2008; Bisson, et al., 2006; Fiscus, et al., 
2006; Moore, et al., 2006; Petti, et al., 2006); and will need to be evaluated in 
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individual clinical settings. Additionally, the definition of virologic failure is an 
obvious factor in determining the prevalence of virologic failure in a population. 
Although some research considers the consequences of different definitions of 
virologic failure (Macias et al., 2005; Raboud et al., 1999; Raboud et al., 1998), it 
remains unclear which level of HIV RNA viral load constitutes the most important 
clinical cutpoint to define virologic failure. Differences regarding negative predictive 
values between different definitions of virologic failure (500, 1000 and 1500 HIV 
RNA copies/mL) appear to be very small (≤2%) and reasonably small (≤7%) for 
prevalence of virologic failure up to 10% and 20% respectively. Differences in 
relative efficiency for different definitions of virologic failure (500, 1000 and 1500 
HIV RNA copies/mL) were also small. In essence, results regarding relative 
efficiency and negative predictive value did not depend on the definition of virologic 
failure. It might be possible to further improve the efficiency of the matrix approach 
(e.g. choosing and individual testing of the cell with largest column and row pool; 
subtracting individual test values from column and row estimates might not be 
optimal). 
Since the goal of virologic monitoring during ART, is to achieve and maintain a 
low prevalence of virologic failure in the population of patients receiving ART, 
another option to achieve low prevalence would be to monitor the population for 
virologic failure at shorter intervals. Recent HIV treatment guidelines recommend 
monitoring viral loads every three to four months (Hammer, et al., 2006); however, 
these recommendations are based solely on expert’s interpretation of the published 
literature (Hammer, et al., 2006), and more frequent monitoring has been proposed 
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based on prospective clinical trial data (Haubrich, et al., 2001). More likely, the 
frequency of virologic monitoring needed to optimize clinical outcomes will vary by 
clinical setting, which would include factors such as the potency, tolerability and 
durability of the available ART regimens, support available for patient adherence and 
prevalence of transmitted drug resistance. Taken together, the methods used to 
monitor for virologic failure during ART will need to be evaluated based on the needs 
of each clinical setting.  
Similarly, each clinical program will most likely have unique requirements for 
assay characteristics (overall costs, turnaround time of results and monitoring 
accuracy). For example, in some areas the overall cost of performing a viral load may 
be the greatest limiting factor for monitoring for virologic failure; therefore, a clinical 
program in this setting might best be served by a method that has the highest relative 
efficiency for the assays, independent of the turnaround time of individual results or 
maximal accuracy. Alternatively, other programs might require more rapid 
turnaround times for obtaining viral load results, such as programs with smaller 
patient populations receiving ART. These settings would require more time to obtain 
enough samples to constitute a pool, and more frequent testing or smaller pool sizes 
or even individual viral load testing might be the most cost-effective. Another factor 
that must be considered for each clinical setting is quality assurance, which will 
mostly depend on the expertise of the personnel performing the assays (sample 
handling, processing and technical consistency with the viral load assay), which 
could lead to errors in pooling, resolution testing and inconsistency in calculating 
viral load results. Similar to choosing a method to screen for virologic failure, the 
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extent and nature of technical training required to perform various pooling 
approaches and maximize quality assurance will need to be evaluated in each local 
laboratory and clinical setting. 
We present characteristics for a variety of algorithms and pool sizes that can 
incorporate available quantitative viral load data and data on how pooling methods 
can be used efficiently and accurately to monitor for virologic failure in patients 
receiving ART. These data could be used by individual laboratory and clinical 
settings to make choices about optimal local virologic monitoring strategies. They 
may also be used to design efficient pooling strategies for other settings where 
screening involves quantitative measures. Although promising, further investigation 
in resource-constrained settings is required to determine if these methods are feasible 
and cost-effective with respect to the factors that could not be included in the 
simulations like turnaround time of results, additional personnel costs in local 
settings, and individual and public health costs of a patient population with virologic 
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Figure 1: Schematic overview of minipool and minipool + algorithm approaches. 
Each circle represents an individual sample, each hexagon a pooled sample.  The 
numbers within the non-shaded circles are viral load values measured in the 
individual samples. Green circles indicate individual samples that will have viral 
loads measured in the next step. Yellow circles indicate samples that might have viral 
loads measured depending on the outcome of the measures for the green circles.  
In step 1 for the minipool approach (A), individual samples (green circles) are 
pooled (hexagon) and a viral load measured in the pooled sample. In this example, 
since the pooled sample is greater than the threshold of interest (here ≤300 copies/mL 
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because there are 5 individual samples in a pool), then all individual samples are 
tested individually in step 2.  
In step 1 for the minipool + algorithm approach (B), individual samples (green and 
yellow circles) are pooled (hexagon) and a viral load measured in the pooled sample. 
In steps 2-4, since the pooled sample is greater than the threshold of interest, 
individual samples of pools with values above the threshold are consecutively tested 
and individual estimates (divided by pool size) are subtracted from pool total 
(hexagon) until the threshold value is reached (red hexagon). Remaining samples 
(grey circles) that have not been tested individually are assumed to be below 
threshold (here ≤1500 copies/mL). Note, estimated values for individual samples will 
typically not add up to estimated values for pooled samples because of assay 
variability. 
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Figure 2: Schematic overview of matrix approach. Each circle represents an 
individual sample, each hexagon a pooled sample.  The numbers within the non-
shaded circles are viral load values measured on individual samples. Viral load values 
for grey circles are assumed to be below the threshold (here ≤1500 copies/mL). Green 
circles indicate samples that will be measured in the next step. Yellow circles indicate 
samples that might be measured depending on the outcome of the measures for the 
individual samples marked by the green circles. Red circles and hexagons indicate 
that no further testing/estimation will be performed for the sample or pool. Note, 
estimated values for individual samples will typically not add up to estimated values 
for pooled samples because of assay variability. 
In step 1 of the matrix approach, individual samples (circles) are pooled across 
rows and columns (hexagons), and viral loads are then measured in each pool. All 
individual samples are considered to be below the threshold level (grey circle) if their 
respective row or column pool has a viral load below the threshold level of interest. 
Individual samples that belong to a row and a column pool that have viral loads 
above the threshold remain ambiguous as to whether or not they contain viral loads 
above the threshold of interest and might be tested individually (green and yellow 
circles). In step 2, the individual sample that belongs to the intersection of the row 
and column pools with the highest viral load values (green circle) has its viral load 
measured. The viral load of this individual sample is divided by the size of the pools 
(here 5), and this value is subtracted from the respective row and column pool totals 
(hexagons), and this subtraction can resolve previously ambiguous samples (yellow 
circles) to be considered below the viral load level of interest (grey circles). In step 3, 
Hosted by The Berkeley Electronic Press
Comparison of Pooling Algorithms             26 
  
this continues until all individual samples belong to a row or column pool that has 
reached the threshold level.  
 
In this example the first individual sample that is tested has a viral load of 9935. 
This value divided by the pool size (9935/5 = 1987) is subtracted from column (1522 
– 1987 < 0) and row estimate (1718 – 1987 < 0).  Samples or rows and columns with 
pool estimates below the threshold (here ≤300) are not tested individually and are 
assumed to be below the threshold (here ≤1500).  
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Figure 3: Relative efficiency of minipool, minipool + algorithm and matrix 
approaches for various pool sizes using a definition of virologic failure of HIV RNA 
≥1500 copies/mL and assay standard deviation (SD) 0.12 copies/mL (on log10 scale).  
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Figure 4: Relative efficiency for minipool, minipool + algorithm and matrix 
approaches with highest (among different pool sizes) relative efficiency compared to 
individual testing using a definition of virologic failure of viral load ≥1500 copies/mL 
and assay standard deviation (SD) 0.12 copies/mL (on log10 scale). 
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